Methods relating to peripheral administration of nogo receptor polypeptides
AssigneesBiogen Idec MA Inc., Yale University
InventorsStephen M. Strittmatter, Daniel H.S. Lee
Life of this patent
Estimating the term…
Abstract
This invention relates to methods of treating diseases involving accumulation of Aβ plaques, including Alzheimer's Disease by the peripheral administration of soluble Nogo receptor polypeptides. The invention also provides methods of increasing the plasma to brain ratio of Aβ peptide and enhancing Aβ peptide clearance via peripheral administration of soluble Nogo receptor polypeptides. This invention also provides methods of improving memory function or inhibiting memory loss via the peripheral administration of soluble Nogo receptor polypeptides. The invention also provides methods of decreasing the size and number of Aβ plaques in a mammal via peripheral administration of soluble Nogo receptor polypeptides.
Claims32
A method of increasing the plasma to brain ratio of Aβ peptide in a mammal, comprising administering to a mammal in need thereof a therapeutically effective amount of a soluble Nogo receptor polypeptide, wherein said administration is peripheral to the central nervous system.
A method of enhancing Aβ clearance from the brain of a mammal, comprising administering to a mammal in need thereof a therapeutically effective amount of a soluble Nogo receptor polypeptide, wherein said administration is peripheral to the central nervous system.
A method of improving memory function or inhibiting memory loss in a mammal comprising administering to a mammal in need thereof a therapeutically effective amount of a soluble Nogo receptor polypeptide, wherein said administration is peripheral to the central nervous system.
A method of reducing the number of Aβ plaques in the brain of a mammal, comprising administering to a mammal in need thereof a therapeutically effective amount of a soluble Nogo receptor polypeptide, wherein said administration is peripheral to the central nervous system.
A method of reducing the size of Aβ plaques in the brain of a mammal, comprising administering to a mammal in need thereof a therapeutically effective amount of a soluble Nogo receptor polypeptide, wherein said administration is peripheral to the central nervous system.
A method of treating a disease associated with Aβ plaque accumulation in a mammal comprising administering to a mammal in need thereof a therapeutically effective amount of a soluble Nogo receptor polypeptide, wherein said administration is peripheral to the central nervous system.
9-11. (canceled)
16-23. (canceled)
25-27. (canceled)
(canceled)
(canceled)
32-36. (canceled)
39-44. (canceled)
46-50. (canceled)
(canceled)
(canceled)
Dependencies are inferred from the claim text.